CME-accredited webinar | Interdisciplinary guidelines for myotonic dystrophy type 1 (DM1) management across the spectrum
NMD4C and Muscular Dystrophy Canada (MDC) are pleased to invite you to a webinar on interdisciplinary guidelines for myotonic dystrophy type 1 (DM1).
This webinar is CME-accredited. The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organizational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
Tuesday, October 6th at 5:00pm ET
If you have any questions, please email
Register HERE
Objectives:
At the end of the presentation, the attendees will be able to identify:
- Key management areas among the most frequent phenotypes of DM1
- Key treatment perspectives in DM1
- Life-threatening complications related to DM1 management
Topics and speakers:
International clinical guidelines for adult DM1: An allied health perspective
Dr. Cynthia Gagnon (NMD4C investigator)
Exercise prescription for adult DM1: What do we know?
Dr. Élise Duchesne (NMD4C member)
International clinical guidelines for congenital DM1
Dr. Craig Campbell (NMD4C investigator) and Dr. Cam-Tu Nguyen
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.